ResearcherStony Brook UniversityNo recent work listed

Komala Ingle

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5092415355. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2023: 1 paper

Papers 1

AUM302, a novel triple kinase PIM/PI3K/mTOR inhibitor, is a potent in vitro pancreatic cancer growth inhibitor. Co-author DOI 10.1371/journal.pone.0294065 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Joseph F. LaComb · 1 shared paper, 2023 · strength 0.24
- Paper AUM302, a novel triple kinase PIM/PI3K/mTOR inhibitor, is a potent in vitro pancreatic cancer growth inhibitor. DOI 10.1371/journal.pone.0294065 ↗
Lee M. Graves · 1 shared paper, 2023 · strength 0.24
- Paper AUM302, a novel triple kinase PIM/PI3K/mTOR inhibitor, is a potent in vitro pancreatic cancer growth inhibitor. DOI 10.1371/journal.pone.0294065 ↗
Agnieszka Beata Bialkowska · 1 shared paper, 2023 · strength 0.24
- Paper AUM302, a novel triple kinase PIM/PI3K/mTOR inhibitor, is a potent in vitro pancreatic cancer growth inhibitor. DOI 10.1371/journal.pone.0294065 ↗
Antonio T. Baines · 1 shared paper, 2023 · strength 0.24
- Paper AUM302, a novel triple kinase PIM/PI3K/mTOR inhibitor, is a potent in vitro pancreatic cancer growth inhibitor. DOI 10.1371/journal.pone.0294065 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.